Monotherapy with anti-CAIX, combination therapy with two immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4), as well as combination therapy with anti-CAIX and anti-PD-1 resulted in a short decrease in tumor volume, followed by renewed growth. The gene discussed is CA9; the disease is neoplasm.